Werewolf Therapeutics, Inc. (HOWL)
| Market Cap | 19.91M -63.0% |
| Revenue (ttm) | 21.00M |
| Net Income | -34.61M |
| EPS | -0.75 |
| Shares Out | 48.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 198,989 |
| Open | 0.4000 |
| Previous Close | 0.3860 |
| Day's Range | 0.3866 - 0.4250 |
| 52-Week Range | 0.2700 - 2.3800 |
| Beta | 0.29 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatm... [Read more]
Financial Performance
Financial StatementsNews
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
WATERTOWN, Mass., July 31, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of cond...
Werewolf Therapeutics Quarterly report: Q2 2026
Werewolf Therapeutics has published its Q2 2026 quarterly earnings report on July 31, 2026.
Werewolf Therapeutics Earnings release: Q2 2026
Werewolf Therapeutics released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condi...
Werewolf Therapeutics Quarterly report: Q1 2026
Werewolf Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Werewolf Therapeutics Earnings release: Q1 2026
Werewolf Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Werewolf Therapeutics hires Piper Sandler to assist in strategic evaluation
Werewolf Therapeutics (HOWL) announced that the company has engaged Piper Sandler & Co. to serve as exclusive financial advisor to assist in a strategic evaluation process. “The company does not…
Werewolf Therapeutics reports Q4 EPS (20c), consensus (35c)
As of December 31, 2025, cash and cash equivalents were $57.1M, compared to $65.7M as of September 30, 2025. The company believes its cash and cash equivalents as of December…
Werewolf Therapeutics to explore range of strategic alternatives
07:07 EDT Werewolf Therapeutics (HOWL) to explore range of strategic alternatives
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value
Werewolf Therapeutics Annual report: Q4 2025
Werewolf Therapeutics has published its Q4 2025 annual report on March 27, 2026.
Werewolf Therapeutics Earnings release: Q4 2025
Werewolf Therapeutics released its Q4 2025 earnings on March 27, 2026, summarizing the period's financial results.
Werewolf Therapeutics to explore strategic alternatives
Earlier this evening, Werewolf Therapeutics (HOWL) “announced that the company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to ma...
Werewolf Therapeutics trading resumes
16:30 EST Werewolf Therapeutics (HOWL) trading resumes
Werewolf Therapeutics trading halted, news pending
16:10 EST Werewolf Therapeutics (HOWL) trading halted, news pending
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of ther...
Werewolf Therapeutics announces 64% workforce reduction
In a regulatory filing, the company said, “On February 9, 2026, the board of directors of Werewolf Therapeutics (HOWL) approved a reduction in force, representing 64% of the company’s workforce.
Citizens downgrades Werewolf Therapeutics on need for capital
Citizens downgraded Werewolf Therapeutics (HOWL) to Market Perform from Outperform without a price target after the company provided updates to its clinical and preclinical pipeline. While WTX-124 and...
Werewolf Therapeutics downgraded to Market Perform from Outperform at Citizens
Citizens analyst Reni Benjamin downgraded Werewolf Therapeutics (HOWL) to Market Perform from Outperform.
Wedbush downgrades Werewolf Therapeutics to Neutral on challenging path
As previously reported, Wedbush downgraded Werewolf Therapeutics (HOWL) to Neutral from Outperform with a price target of $1, down from $3. The firm notes the company reported updates from ongoing…
Werewolf Therapeutics downgraded to Neutral from Outperform at Wedbush
Wedbush downgraded Werewolf Therapeutics (HOWL) to Neutral from Outperform with a price target of $1, down from $3.
Werewolf Therapeutics price target lowered to $4 from $10 at H.C. Wainwright
H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Werewolf Therapeutics (HOWL) to $4 from $10 and keeps a Buy rating on the shares after the company announced…
Werewolf Therapeutics provides pipeline update, review of INDUKINE data
Werewolf Therapeutics (HOWL) announced a pipeline update, including a review of recent data for its INDUKINE programs, and a business overview of its priorities for 2026 that includes a focus…
Werewolf Therapeutics announces 2025 priorities
The Phase 1/1b clinical trial of WTX-124 is expected to be completed in the first half of 2026, with an additional data update planned to be provided at that time.
Werewolf Therapeutics Announces Pipeline and Business Updates
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with potential best-in...